trending Market Intelligence /marketintelligence/en/news-insights/trending/yd7yvem8q9l_qemwr50ytw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Affimed puts early trials of blood cancer drug on hold after patient death

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Affimed puts early trials of blood cancer drug on hold after patient death

German drug developer Affimed NV put on hold two early stage clinical studies testing an investigational immunotherapy to treat blood cancer following the death of one of the patients and other life-threatening events.

The immunotherapy AFM11, a CD19/CD3-targeting T cell engager, is being evaluated to treat CD19 positive B cell non-Hodgkin lymphoma, or NHL, in patients whose cancer came back or was unresponsive to treatment. The immunotherapy is also being tested on patients with acute lymphoblastic leukemia, or ALL.

Affimed said in its Oct. 8 press release that a patient in the ALL study died and two life-threatening events occurred in the NHL study. These adverse events happened in the highest dose arms of both studies, the company added. The two studies enrolled 33 patients.

Non-Hodgkin's lymphoma is a group of blood cancers that originate in the lymphatic system, an important part of the immune system. Patients with non-Hodgkin's lymphoma develop tumors in white blood cells known as lymphocytes.

SNL Image SNL Image

Heidelberg, Germany-based Affimed plans to release an update for the future plans of its AFM11 program after conducting a review of the study with global health authorities, the Safety Monitoring Committees and the clinical investigators of the studies.

Affimed has another immunotherapy in development — AFM13 — which helped to reduce cancer in an early stage trial of the drug in combination with Merck & Co. Inc.'s Keytruda. The German biopharmaceutical company in August signed a collaboration deal with Swiss drugmaker Roche Holding AG to develop cancer treatments.